NASDAQ:ZSAN - Zosano Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.05 -0.03 (-0.74 %)
(As of 05/23/2018 01:00 AM ET)
Previous Close$4.05
Today's Range$3.95 - $4.16
52-Week Range$3.61 - $33.60
Volume240,583 shs
Average Volume1.03 million shs
Market Capitalization$51.60 million
P/E Ratio-0.24
Dividend YieldN/A
Beta1.93

About Zosano Pharma (NASDAQ:ZSAN)

Zosano Pharma logoZosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

Receive ZSAN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZSAN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZSAN
CUSIPN/A
Phone510-745-1200

Debt

Debt-to-Equity RatioN/A
Current Ratio0.52
Quick Ratio0.52

Price-To-Earnings

Trailing P/E Ratio-0.24
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$310,000.00
Price / Sales156.38
Cash FlowN/A
Price / CashN/A
Book Value$3.57 per share
Price / Book1.13

Profitability

EPS (Most Recent Fiscal Year)($16.82)
Net Income$-29,100,000.00
Net MarginsN/A
Return on Equity-287.27%
Return on Assets-136.43%

Miscellaneous

Employees51
Outstanding Shares11,970,000

Zosano Pharma (NASDAQ:ZSAN) Frequently Asked Questions

What is Zosano Pharma's stock symbol?

Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."

When did Zosano Pharma's stock split? How did Zosano Pharma's stock split work?

Zosano Pharma's stock reverse split on the morning of Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.

How were Zosano Pharma's earnings last quarter?

Zosano Pharma Corp (NASDAQ:ZSAN) posted its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported ($4.16) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($4.60) by $0.44. View Zosano Pharma's Earnings History.

When is Zosano Pharma's next earnings date?

Zosano Pharma is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Zosano Pharma.

Are investors shorting Zosano Pharma?

Zosano Pharma saw a drop in short interest in the month of April. As of April 30th, there was short interest totalling 924,167 shares, a drop of 43.0% from the April 13th total of 1,622,142 shares. Based on an average daily trading volume, of 523,613 shares, the days-to-cover ratio is presently 1.8 days. Currently, 8.1% of the shares of the stock are sold short.

Who are some of Zosano Pharma's key competitors?

Who are Zosano Pharma's key executives?

Zosano Pharma's management team includes the folowing people:
  • Mr. John P. Walker, Chairman, CEO & Pres (Age 69)
  • Ms. Georgia L. Erbez, Chief Bus. Officer, CFO & Principal Accounting Officer (Age 51)
  • Dr. Donald J. Kellerman Pharm.D., VP of Clinical Devel. & Medical Affairs (Age 63)
  • Mr. Eric Scharin, VP of Operations and Engineering (Age 52)
  • Dr. Thorsten von Stein M.D., Ph.D., Chief Medical Officer (Age 56)

When did Zosano Pharma IPO?

(ZSAN) raised $47 million in an initial public offering on Tuesday, January 27th 2015. The company issued 4,300,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO.

Has Zosano Pharma been receiving favorable news coverage?

News coverage about ZSAN stock has trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zosano Pharma earned a media sentiment score of 0.15 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.62 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Zosano Pharma's major shareholders?

Zosano Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include AISLING CAPITAL IV, LP (13.40%), Nexthera Capital LP (5.85%), Iguana Healthcare Management LLC (4.18%), CVI Holdings LLC (3.13%), Sabby Management LLC (1.95%) and Hawk Ridge Capital Management LP (1.67%). Company insiders that own Zosano Pharma stock include Amzak Capital Management, Llc, Donald J Kellerman, Enterprise Associates 12 New, Georgia Erbez, John Peter Walker, Kenneth Greathouse, Konstantinos Alataris and M James Barrett. View Institutional Ownership Trends for Zosano Pharma.

Which institutional investors are buying Zosano Pharma stock?

ZSAN stock was bought by a variety of institutional investors in the last quarter, including Nexthera Capital LP, Iguana Healthcare Management LLC, CVI Holdings LLC, Sabby Management LLC, Hawk Ridge Capital Management LP, Millennium Management LLC, Verition Fund Management LLC and Tiverton Asset Management LLC. Company insiders that have bought Zosano Pharma stock in the last two years include Donald J Kellerman, Georgia Erbez, John Peter Walker, Kenneth Greathouse and Konstantinos Alataris. View Insider Buying and Selling for Zosano Pharma.

How do I buy shares of Zosano Pharma?

Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zosano Pharma's stock price today?

One share of ZSAN stock can currently be purchased for approximately $4.05.

How big of a company is Zosano Pharma?

Zosano Pharma has a market capitalization of $51.60 million and generates $310,000.00 in revenue each year. The biotechnology company earns $-29,100,000.00 in net income (profit) each year or ($16.82) on an earnings per share basis. Zosano Pharma employs 51 workers across the globe.

How can I contact Zosano Pharma?

Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at 510-745-1200 or via email at [email protected]


MarketBeat Community Rating for Zosano Pharma (ZSAN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  231
MarketBeat's community ratings are surveys of what our community members think about Zosano Pharma and other stocks. Vote "Outperform" if you believe ZSAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZSAN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Zosano Pharma (NASDAQ:ZSAN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/ABuyBuy
Consensus Rating Score: N/AN/A3.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/A$70.00$70.00
Price Target Upside: N/AN/A97.74% upside97.74% upside

Zosano Pharma (NASDAQ:ZSAN) Consensus Price Target History

Price Target History for Zosano Pharma (NASDAQ:ZSAN)

Zosano Pharma (NASDAQ:ZSAN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/24/2017Piper Jaffray CompaniesInitiated CoverageOverweight$80.00LowView Rating Details
3/11/2017Roth CapitalSet Price TargetBuy$60.00MediumView Rating Details
8/11/2016Ladenburg ThalmannDowngradeBuy ➝ NeutralN/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Zosano Pharma (NASDAQ:ZSAN) Earnings History and Estimates Chart

Earnings by Quarter for Zosano Pharma (NASDAQ:ZSAN)

Zosano Pharma (NASDAQ ZSAN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018N/AView Earnings Details
5/15/2018Q1 2018($4.60)($4.16)ViewListenView Earnings Details
3/12/2018Q4 2017($4.80)($3.80)ViewN/AView Earnings Details
11/9/2017Q3 2017($3.00)($4.00)ViewN/AView Earnings Details
8/10/2017Q2 2017($3.00)($3.40)ViewN/AView Earnings Details
5/9/2017Q1 2017($6.00)($6.80)ViewListenView Earnings Details
3/1/2017Q4 2016($9.00)($9.20)ViewN/AView Earnings Details
11/9/2016Q3 2016($13.00)($10.40)ViewN/AView Earnings Details
8/10/2016Q2($10.00)($10.80)ViewN/AView Earnings Details
5/12/2016Q1($11.20)($13.60)ViewListenView Earnings Details
3/29/2016Q4($13.40)($12.80)ViewListenView Earnings Details
11/9/2015Q315($12.20)($14.40)$380.00 millionViewN/AView Earnings Details
8/12/2015Q215($10.60)($12.60)$0.22 million$0.10 millionViewN/AView Earnings Details
5/11/2015Q1 2015($8.60)($9.40)$0.50 million$0.22 millionViewN/AView Earnings Details
3/25/2015($12.80)($22.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Zosano Pharma (NASDAQ:ZSAN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Zosano Pharma (NASDAQ ZSAN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.83%
Institutional Ownership Percentage: 40.42%
Insider Trading History for Zosano Pharma (NASDAQ:ZSAN)
Institutional Ownership by Quarter for Zosano Pharma (NASDAQ:ZSAN)

Zosano Pharma (NASDAQ ZSAN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/27/2018Amzak Capital Management, LlcMajor ShareholderSell88,281$8.40$741,560.40View SEC Filing  
12/6/2017Kenneth GreathouseDirectorBuy55,000$0.61$33,550.00200,000View SEC Filing  
12/1/2017Kenneth GreathouseDirectorBuy95,000$0.62$58,900.0095,000View SEC Filing  
11/15/2017Kenneth GreathouseDirectorBuy50,000$0.62$31,000.0035,000View SEC Filing  
5/25/2017Georgia ErbezCFOBuy68,000$1.32$89,760.00115,750View SEC Filing  
5/25/2017John Peter WalkerCEOBuy73,716$1.36$100,253.76169,344View SEC Filing  
2/13/2017Enterprise Associates 12 NewMajor ShareholderSell1,099,996$2.01$2,210,991.96View SEC Filing  
9/16/2016Enterprise Associates 12 NewMajor ShareholderSell7,471$0.75$5,603.25View SEC Filing  
9/13/2016Enterprise Associates 12 NewMajor ShareholderSell10,000$0.74$7,400.00View SEC Filing  
8/29/2016M James BarrettMajor ShareholderSell50,000$1.01$50,500.005View SEC Filing  
8/24/2016Enterprise Associates 12 NewMajor ShareholderSell1,200$1.21$1,452.00View SEC Filing  
8/19/2016Donald J KellermanVPBuy15,920$1.32$21,014.4015,920View SEC Filing  
8/19/2016Georgia ErbezCFOBuy47,750$1.32$63,030.0047,750View SEC Filing  
8/19/2016John Peter WalkerDirectorBuy63,700$1.32$84,084.0063,700View SEC Filing  
8/19/2016Konstantinos AlatarisCEOBuy127,389$1.32$168,153.48View SEC Filing  
7/21/2016Enterprise Associates 12 NewMajor ShareholderSell23,681$1.27$30,074.87View SEC Filing  
7/13/2016Enterprise Associates 12 NewMajor ShareholderSell13,382$1.20$16,058.40View SEC Filing  
1/30/2015Enterprise Associates 12 NewMajor ShareholderBuy23,457$11.00$258,027.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Zosano Pharma (NASDAQ ZSAN) News Headlines

Source:
DateHeadline
Zosano Appoints Steven A. Elms to Board of DirectorsZosano Appoints Steven A. Elms to Board of Directors
finance.yahoo.com - May 22 at 8:39 AM
Zosano Pharmas (ZSAN) CEO John Walker on Q1 2018 Results - Earnings Call TranscriptZosano Pharma's (ZSAN) CEO John Walker on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 16 at 8:53 AM
Zosano Pharma (ZSAN) Issues  Earnings ResultsZosano Pharma (ZSAN) Issues Earnings Results
www.americanbankingnews.com - May 15 at 9:33 PM
Zosano Pharma Reports First Quarter 2018 Financial Results and Operational UpdateZosano Pharma Reports First Quarter 2018 Financial Results and Operational Update
finance.yahoo.com - May 15 at 5:27 PM
BRIEF-Zosano Reaches Enrollment Milestone In M207-Adam Long-Term Safety StudyBRIEF-Zosano Reaches Enrollment Milestone In M207-Adam Long-Term Safety Study
www.reuters.com - May 14 at 9:05 AM
Zosano Reaches Another Enrollment Milestone in M207-ADAM Long-term Safety StudyZosano Reaches Another Enrollment Milestone in M207-ADAM Long-term Safety Study
finance.yahoo.com - May 14 at 9:05 AM
Zosano Pharma Corp (ZSAN) Short Interest Down 43.0% in AprilZosano Pharma Corp (ZSAN) Short Interest Down 43.0% in April
www.americanbankingnews.com - May 14 at 1:10 AM
Zosano Pharma (ZSAN) Scheduled to Post Earnings on TuesdayZosano Pharma (ZSAN) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - May 10 at 1:00 PM
Zosano Pharma to Host Conference Call on First Quarter 2018 Financial Results and Provide Operational UpdateZosano Pharma to Host Conference Call on First Quarter 2018 Financial Results and Provide Operational Update
finance.yahoo.com - May 8 at 5:11 PM
Zosano Pharma (ZSAN) Lifted to "Hold" at ValuEngineZosano Pharma (ZSAN) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - May 2 at 1:15 PM
Zosano Pharma (ZSAN) Scheduled to Post Quarterly Earnings on MondayZosano Pharma (ZSAN) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 9:22 AM
Zosano Pharma Corp (ZSAN) Expected to Announce Earnings of -$5.40 Per ShareZosano Pharma Corp (ZSAN) Expected to Announce Earnings of -$5.40 Per Share
www.americanbankingnews.com - April 30 at 1:14 AM
Zosano Pharma (ZSAN) Stock Rating Lowered by ValuEngineZosano Pharma (ZSAN) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 16 at 7:35 PM
Form 3 ELMS STEVE For: Mar 29 Filed by: Zosano Pharma CorpForm 3 ELMS STEVE For: Mar 29 Filed by: Zosano Pharma Corp
www.streetinsider.com - April 10 at 9:01 AM
Zosano Pharma (ZSAN) Raised to "Sell" at ValuEngineZosano Pharma (ZSAN) Raised to "Sell" at ValuEngine
www.americanbankingnews.com - April 9 at 4:05 PM
Zosano Pharmas (ZSAN) Operational Update Conference Call (Transcript)Zosano Pharma's (ZSAN) Operational Update Conference Call (Transcript)
seekingalpha.com - April 5 at 10:46 AM
Zosano Pharma (ZSAN) Stock Rating Upgraded by ValuEngineZosano Pharma (ZSAN) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 3 at 11:31 PM
Here’s What Just Happened With Zosano Pharma Corporation And Pfizer IncHere’s What Just Happened With Zosano Pharma Corporation And Pfizer Inc
finance.yahoo.com - April 3 at 5:09 PM
Zosano Pharma closes $50M equity offeringZosano Pharma closes $50M equity offering
seekingalpha.com - April 3 at 5:09 PM
Zosano Pharma to Host Conference Call to Provide Operational UpdateZosano Pharma to Host Conference Call to Provide Operational Update
feeds.benzinga.com - April 2 at 1:52 PM
Zosano prices stock offering at $5; shares down 44%Zosano prices stock offering at $5; shares down 44%
seekingalpha.com - March 29 at 5:07 PM
Zosano Pharma (ZSAN) Prices 10 Million Share Offering at $5/ShareZosano Pharma (ZSAN) Prices 10 Million Share Offering at $5/Share
www.streetinsider.com - March 29 at 5:07 PM
Zosano Pharma readies stock offering; shares down 25% premarketZosano Pharma readies stock offering; shares down 25% premarket
seekingalpha.com - March 29 at 8:55 AM
Zosano Pharma (ZSAN) Shares Decline on Concerns About Offering PriceZosano Pharma (ZSAN) Shares Decline on Concerns About Offering Price
www.streetinsider.com - March 29 at 8:55 AM
Zosano Pharmas stock plummets after stock offering filed, assumed to price at deep discountZosano Pharma's stock plummets after stock offering filed, assumed to price at deep discount
finance.yahoo.com - March 29 at 8:55 AM
Zacks: Zosano Pharma Corp (ZSAN) Given Average Rating of "Strong Buy" by AnalystsZacks: Zosano Pharma Corp (ZSAN) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - March 28 at 7:32 PM
Zosano Pharma Corp (ZSAN) Expected to Post Earnings of -$5.40 Per ShareZosano Pharma Corp (ZSAN) Expected to Post Earnings of -$5.40 Per Share
www.americanbankingnews.com - March 27 at 3:04 AM
Zosano Pharma (ZSAN) Cut to "Strong Sell" at ValuEngineZosano Pharma (ZSAN) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 25 at 12:52 AM
Wired News – Zosano Reports Enrollment Milestone in its M207-ADAM StudyWired News – Zosano Reports Enrollment Milestone in its M207-ADAM Study
finance.yahoo.com - March 20 at 8:58 AM
Zosano Pharma (ZSAN) Announced 100th Patient Enrolled in M207-ADAM Migraine StudyZosano Pharma (ZSAN) Announced 100th Patient Enrolled in M207-ADAM Migraine Study
www.streetinsider.com - March 16 at 6:05 PM
Should You Buy Zosano Pharma Corporation (NASDAQ:ZSAN) Now?Should You Buy Zosano Pharma Corporation (NASDAQ:ZSAN) Now?
finance.yahoo.com - March 16 at 6:05 PM
Zosano Reaches Enrollment Milestone in M207-ADAM Long-term Safety StudyZosano Reaches Enrollment Milestone in M207-ADAM Long-term Safety Study
finance.yahoo.com - March 16 at 8:52 AM
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Operational Update - GlobeNewswire (press release)Zosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Operational Update - GlobeNewswire (press release)
globenewswire.com - March 12 at 6:13 PM
Zosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Operational UpdateZosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Operational Update
finance.yahoo.com - March 12 at 12:20 PM
-$4.80 EPS Expected for Zosano Pharma Corp (ZSAN) This Quarter-$4.80 EPS Expected for Zosano Pharma Corp (ZSAN) This Quarter
www.americanbankingnews.com - March 9 at 9:30 PM
Zosano Pharma set to add to rally, up 20% premarketZosano Pharma set to add to rally, up 20% premarket
seekingalpha.com - March 9 at 6:17 PM
The Market In 5 Minutes: Trump And Kim Jung Un, Toys R Us Liquidation, Zosanos Move, Big Payrolls BeatThe Market In 5 Minutes: Trump And Kim Jung Un, Toys 'R' Us Liquidation, Zosano's Move, Big Payrolls Beat
finance.yahoo.com - March 9 at 6:17 PM
36 Stocks Moving In Fridays Mid-Day Session36 Stocks Moving In Friday's Mid-Day Session
feeds.benzinga.com - March 9 at 2:43 PM
Zosano Pharma Is The Latest Low Float Stock To Make A Huge MoveZosano Pharma Is The Latest Low Float Stock To Make A Huge Move
www.msn.com - March 8 at 6:10 PM
Report: Developing Opportunities within Owens & Minor, Zosano Pharma, Organovo, Summit Materials, Ralph Lauren, and Clearside Biomedical — Future Expectations, Projections Moving into 2018Report: Developing Opportunities within Owens & Minor, Zosano Pharma, Organovo, Summit Materials, Ralph Lauren, and Clearside Biomedical — Future Expectations, Projections Moving into 2018
finance.yahoo.com - March 8 at 8:52 AM
 Zosano Pharma Corp (ZSAN) Receives Consensus Recommendation of "Strong Buy" from Brokerages Zosano Pharma Corp (ZSAN) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - March 8 at 5:38 AM
31 Stocks Moving In Wednesdays Mid-Day Session31 Stocks Moving In Wednesday's Mid-Day Session
feeds.benzinga.com - March 7 at 2:12 PM
 Zosano Pharma Corp (ZSAN) Given $80.00 Consensus Target Price by Brokerages Zosano Pharma Corp (ZSAN) Given $80.00 Consensus Target Price by Brokerages
www.americanbankingnews.com - March 3 at 5:16 PM
Zosano Pharma (ZSAN) Announces Issuance of New U.S. Patent Covering M207Zosano Pharma (ZSAN) Announces Issuance of New U.S. Patent Covering M207
www.streetinsider.com - March 2 at 5:45 PM
Zosano Pharma Announces Issuance of New U.S. Patent Covering M207 as an Acute Treatment for MigraineZosano Pharma Announces Issuance of New U.S. Patent Covering M207 as an Acute Treatment for Migraine
finance.yahoo.com - March 2 at 8:41 AM
Zosano Pharma Corp (ZSAN) Major Shareholder Sells $741,560.40 in StockZosano Pharma Corp (ZSAN) Major Shareholder Sells $741,560.40 in Stock
www.americanbankingnews.com - February 28 at 6:16 PM
Today’s Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Zosano PharmaToday’s Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Zosano Pharma
finance.yahoo.com - February 27 at 8:45 AM
Zosano Pharma Corp (ZSAN) Expected to Announce Earnings of -$4.80 Per ShareZosano Pharma Corp (ZSAN) Expected to Announce Earnings of -$4.80 Per Share
www.americanbankingnews.com - February 21 at 5:24 AM
Zosano Pharma (ZSAN) Scheduled to Post Quarterly Earnings on TuesdayZosano Pharma (ZSAN) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 20 at 4:30 AM
ETF Preview: ETFs, Futures Point to Modest Gains Following CPI, Retail Sales DataETF Preview: ETFs, Futures Point to Modest Gains Following CPI, Retail Sales Data
www.nasdaq.com - February 14 at 9:37 AM

SEC Filings

Zosano Pharma (NASDAQ:ZSAN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Zosano Pharma (NASDAQ:ZSAN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Zosano Pharma (NASDAQ ZSAN) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.